What's New in Lyme Disease Save

Little has changed on the diagnostic and therapeutic approaches to Lyme disease in last 25 years. Two-tier antibody serology remains standard, and short-course doxycycline, amoxicillin, or cefuroxime remains first-line therapy . Yet, Lyme disease is one of the most common vector-borne illness in the US - case counts have tripled: from ~21,000 CDC-reported cases two decades ago to 89,000+ in 2023, with estimated true annual US incidence around 476,000 (versus 200,000 in western Europe).

Diagnostics Challenges. The central limitation of two-tier serology is the 2–6 week antibody-response lag, creating a false-negative window early in infection.  Direct detection remains technically difficult because B burgdorferi is tissue-sequestered and present in blood only at very low copy number. Researchers are pursuing PCR-based direct detection of bacterial DNA/antigen and host-response signatures (gene-expression patterns, potentially AI-assisted) to distinguish Lyme from mimics. NIH-funded longitudinal cohorts are also tracking immune and autoantibody markers from early infection to identify predictors of posttreatment Lyme disease syndrome (PTLDS) — clinically analogous to long COVID, with no established treatment.

Lyme Vaccines. Pfizer/Valneva's multivalent OspA-based candidate LB6V is the most advanced program, having completed phase 3 testing (participants as young as age 5) with reported 73% efficacy against Lyme disease — missing its primary statistical endpoint due to lower-than-expected case accrual in the trial, but deemed clinically meaningful by developers and now under FDA review. But caution and skepticism persists: it reuses the same OspA antigen as the withdrawn 1998 LYMErix vaccine (minus the epitope implicated in prior safety concerns), offers all-or-none rather than disease-attenuating protection, and requires 3 priming doses over 9 months plus a booster — a schedule several experts doubt will achieve durable uptake, particularly as climate-driven tick-season lengthening may outlast vaccine-conferred immunity.

Prevention. Two nonvaccine strategies stand out: (1) an OspA-targeting monoclonal antibody (Tonix Pharmaceuticals) offering protection within 2 days of infusion, with an estimated 5–6 month half-life — attractive for discrete high-exposure windows, though likely requiring costly annual infusion; and (2) oral lotilaner (Tarsus Pharmaceuticals), an acaricidal drug already used in veterinary and ophthalmic (demodex blepharitis) settings, designed to kill attached ticks before the ~36-hour transmission threshold is reached.

While nothing changes practice today, the future (years away) suggests new the possibility of options. For now experts uniformly stress that behavioral basics — repellents, protective clothing, and tick checks. For rheumatologists, the PTLDS biomarker work is encouraging and may eventually affect management of Lyme arthritis and post-infectious presentations.